Preventive care in prostate cancer patients: following diagnosis and for five-year survivors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Prostate cancer is the most common male cancer. Survival rates are high, making preventive care maintenance important. Factors associated with prostate-cancer cases’ preventive care in the short-term (Year 1) and long-term (Year 5), and how survivors’ care compares to non-cancer controls, require study.
This retrospective, controlled SEER-Medicare study included loco-regional prostate cancer cases age ≥66 in fee-for-service Medicare diagnosed in 2000 and surviving ≥12 months, and non-cancer controls matched to cases on socio-demographics and survival. Outcomes included influenza vaccination, cholesterol screening, and colorectal cancer screening. Independent variables were number of physician visits, physician specialties visited, initial prostate cancer treatment, socio-demographic characteristics, and case–control status.
There were 13,507 cases and 13,507 controls in Year 1, and 10,482 cases and 10,482 controls in Year 5. In Years 1 and 5, total number of visits (6/6 outcomes) and primary care provider (PCP) visits (5/6 outcomes) were most consistently associated with preventive care receipt. In Year 1, prostate cancer cases were more likely than controls to receive influenza vaccination (48% vs. 45%) but less likely to receive colorectal cancer screening (29% vs. 31%) (both p < 0.0001). In Year 5, prostate cancer cases remained more likely than controls to receive influenza vaccination (46% vs. 44%; p < 0.0001).
Differences in survivors’ short-term preventive care did not lead to worse long-term preventive care. The number of physician visits, particularly PCP visits, are important factors associated with appropriate care.
Implications for Cancer Survivors
PCP involvement in prostate cancer patients’ care is critical both during treatment and for long-term survivors.
- Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington: National Academy Press; 2005.
- Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors vs. controls: changes from 1998–2002. J Clin Oncol. 2009;27:1054–61. CrossRef
- Snyder CF, Frick KD, Peairs KS, Kantsiper ME, Herbert RJ, Blackford AL, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24:469–74. CrossRef
- Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–51. CrossRef
- Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev. 2006;30:52–7. CrossRef
- Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9. CrossRef
- Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med. 2008;23:254–9. CrossRef
- Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003;21:1161–6. CrossRef
- Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–9. CrossRef
- Yu X, McBean M, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. J Cancer Surviv. 2007;1:275–82. CrossRef
- American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2010.
- American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
- National Cancer Institute. Cancer Stat Fact Sheets: Prostate. Available from: http://seer.cancer.gov/statfacts/html/prost.html
- National Cancer Institute. SEER-Medicare: Brief description of the SEER-Medicare database. Available from: http://healthservices.cancer.gov/seermedicare/overview/brief.html
- National Cancer Institute. Number of persons by race and Hispanic ethnicity for SEER participants. Available from: http://seer.cancer.gov/registries/data.html
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83. CrossRef
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9. CrossRef
- Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67. CrossRef
- Snyder CF, Frick KD, Blackford AL, Herbert RJ, Neville BA, Carducci MA, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010;116(23):5391–9. CrossRef
- Preventive care in prostate cancer patients: following diagnosis and for five-year survivors
Journal of Cancer Survivorship
Volume 5, Issue 3 , pp 283-291
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Prostate cancer
- Preventive care
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
- 2. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
- 3. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 6. 624 N. Broadway, Room 657, Baltimore, MD, 21205, USA
- 4. Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA, USA
- 5. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada